Beijing Yimiao Shenzhou Pharmaceutical Technology

Haidian, China Founded: 2015 • Age: 11 yrs
Developer of AVV cell therapy for the treatment of cancer

About Beijing Yimiao Shenzhou Pharmaceutical Technology

Beijing Yimiao Shenzhou Pharmaceutical Technology is a company based in Haidian (China) founded in 2015.. Beijing Yimiao Shenzhou Pharmaceutical Technology has raised $42.81 million across 6 funding rounds from investors including GF Securities, Shengjing 360 and Zhongguancun Science City. Beijing Yimiao Shenzhou Pharmaceutical Technology operates in a competitive market with competitors including Jazz Pharmaceuticals, Insitro, BridgeBio, Celgene and ATAI, among others.

  • Headquarter Haidian, China
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $42.81 M (USD)

    in 6 rounds

  • Latest Funding Round
  • Investors
    GF Securities

    & 13 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Beijing Yimiao Shenzhou Pharmaceutical Technology

Beijing Yimiao Shenzhou Pharmaceutical Technology has successfully raised a total of $42.81M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round
  • First Round

    (24 Nov 2017)

  • Investors Count 14
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2022 Amount Series D - Beijing Yimiao Shenzhou Pharmaceutical Technology Valuation Zhongguancun Science City
Nov, 2021 Amount Series D - Beijing Yimiao Shenzhou Pharmaceutical Technology Valuation China Life Insurance
Dec, 2020 Amount Series C - Beijing Yimiao Shenzhou Pharmaceutical Technology Valuation SDIC Venture Capital Management
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Beijing Yimiao Shenzhou Pharmaceutical Technology

Beijing Yimiao Shenzhou Pharmaceutical Technology has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include GF Securities, Shengjing 360 and Zhongguancun Science City. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
A European venture capital fund focused on deep tech investments.
Founded Year Domain Location
Private equity investments are managed from bases in China.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Beijing Yimiao Shenzhou Pharmaceutical Technology

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Beijing Yimiao Shenzhou Pharmaceutical Technology

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Beijing Yimiao Shenzhou Pharmaceutical Technology Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Beijing Yimiao Shenzhou Pharmaceutical Technology

Beijing Yimiao Shenzhou Pharmaceutical Technology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Insitro, BridgeBio, Celgene and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
An AI-enabled platform is developed for infectious disease treatment.
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
Therapies for cancer and inflammatory diseases are developed.
domain founded_year HQ Location
A biopharmaceutical company accelerating innovative mental health treatments.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Beijing Yimiao Shenzhou Pharmaceutical Technology

Frequently Asked Questions about Beijing Yimiao Shenzhou Pharmaceutical Technology

When was Beijing Yimiao Shenzhou Pharmaceutical Technology founded?

Beijing Yimiao Shenzhou Pharmaceutical Technology was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Beijing Yimiao Shenzhou Pharmaceutical Technology located?

Beijing Yimiao Shenzhou Pharmaceutical Technology is headquartered in Haidian, China. It is registered at Haidian, Beijing, China.

Is Beijing Yimiao Shenzhou Pharmaceutical Technology a funded company?

Beijing Yimiao Shenzhou Pharmaceutical Technology is a funded company, having raised a total of $42.81M across 6 funding rounds to date.

What does Beijing Yimiao Shenzhou Pharmaceutical Technology do?

Beijing Yimiao Shenzhou Pharmaceutical Technology is a developer of AVV cell therapy for the treatment of cancer. It offers treatment for malignant tumors by the application of CART-T technology and gene cell drugs. It also develops a gene engineering vector technology platform for the delivery of lentiviral vectors for the preparation of CAR-T cell products. Its products include IM19, IM21, and IM23 which are in the clinical stage.

Who are the top competitors of Beijing Yimiao Shenzhou Pharmaceutical Technology?

Beijing Yimiao Shenzhou Pharmaceutical Technology's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.

Who are Beijing Yimiao Shenzhou Pharmaceutical Technology's investors?

Beijing Yimiao Shenzhou Pharmaceutical Technology has 14 investors. Key investors include GF Securities, Shengjing 360, Zhongguancun Science City, Innovation Industries, and China Life Private Equity.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available